首页> 外文期刊>Open Journal of Nephrology >Sequential Combination Diuretic-Therapy for Massive Fluid Overload in Furosemide-Refractory Patients with Diabetic Kidney Disease
【24h】

Sequential Combination Diuretic-Therapy for Massive Fluid Overload in Furosemide-Refractory Patients with Diabetic Kidney Disease

机译:糖尿病肾病肥料耐火患者大规模流体过载的顺序组合利尿疗法

获取原文
       

摘要

Patients with renal disease are at risk of fluid overload which escalates as the disease progresses. In the present study, we evaluated the efficacy of sequential combination diuretic-therapy (SCDT) in management of massive fluid overload in Furosemide-refractory renal patients. The added diuretics were Spironolactone 25 mg daily for 3 days, to those without risk of hyperkalemia, followed by Hydrochlorothiazide 25 mg/Metolazone 5 mg daily for 3 more days. Excluded patients were those with 1) acute renal disease, 2) echocardiographic evidence of: a) left ventricular ejection fraction < 40%, b) significant stenotic or incompetent valvular disease, c) ASD or VSD, d) significant pericardial disease, and 3) significant limb venous disease or on drugs likely to cause limb-oedema. To assess the extent of fluid overload; clinical examination was complemented with radiological imaging as well as echocardiographic measurement of systolic pulmonary arterial pressure (sPAP). SCDT led to significant symptomatic, clinical, and radiological improvement of fluid overload without significant side effects. The latter were limited to hyperkalemia and hyponatremia which improved with dietary compliance. Moreover, hyperkalemia improved after subsequent addition of Thiazide/Metolazone. SCDT led to significant (p < 0.001) increase in fractional excretion of sodium and decrease in body weight and sPAP. In conclusion; SCDT is a safe and efficacious measure to control fluid overload in patients with renal diseases.
机译:随着疾病的进展,肾病患者有液体过载的风险。在本研究中,我们评估了序贯组合利尿治疗(SCDT)在呋塞米耐火肾患者大规模流体过载管理中的疗效。将添加的利尿剂每日25毫克为25毫克,持续3天,没有高钾血症风险的人,其次是盐酸亚嗪酰胺25mg /甲基酮5毫克每天持续3天。被排除的患者是1)急性肾病,2)超声心动图证据:a)左心室喷射分数<40%,b)显着的狭窄或无能的瓣膜疾病,c)asd或vsd,d)显着的心包病,3 )显着的肢体静脉疾病或可能导致肢体水肿的药物。评估流体过载的程度;临床检查与收缩肺动脉压(SPAP)的放射性成像以及超声心动图测量互动。 SCDT导致了液体过载的显着症状,临床和放射性,而无明显副作用。后者仅限于高钾血症和低钠血症,提高饮食依从性。此外,高钾血症后续加入噻嗪类/茂密酮后改善。 SCDT导致显着的(P <0.001)增加钠分数和体重减轻和阀门的减少。综上所述; SCDT是一种安全而有效的措施,可控制肾病患者的流体过载。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号